Varicella: Difference between revisions

No edit summary
 
(32 intermediate revisions by 9 users not shown)
Line 2: Line 2:
*Caused by [[varicella zoster virus]] causing varicella (chicken pox) and later zoster ([[Shingles]])  
*Caused by [[varicella zoster virus]] causing varicella (chicken pox) and later zoster ([[Shingles]])  
*Contagious until last lesion crusts over
*Contagious until last lesion crusts over
**Fluid from open vesicles contains live virus <ref name="Bode">Sara Bode; Contagious Exanthematous Diseases. ''Quick References 2022''; 10.1542/aap.ppcqr.396150</ref>
*Incubation period is 10-21 days with symptoms starting around day 14 <ref name="Bode"/>


==Diagnosis==
{{Herpes viruses}}
 
==Clinical Features==
[[File:Vicki Pandit - Howrah 2014-04-06 9845.jpg|thumb|Chickenpox rash on face.]]
[[File:Varicela Rash.jpg|thumbnail|Male with varicella rash: lesions in various stages of development]]
[[File:Varicela Rash.jpg|thumbnail|Male with varicella rash: lesions in various stages of development]]
[[File:Chickenpox blister.jpg|thumbnail|Classic blister during early stage of lesion development]]
[[File:Chickenpox blister.jpg|thumbnail|Classic blister during early stage of lesion development]]
*Pruritic generalized vesicular exanthem w/ mild systemic manifestations
*[[pruritus|Pruritic]] generalized vesicular exanthem with mild systemic manifestations
*Usually affects children <10y
*Usually affects children <10y
*Rash
 
**Starts on trunk or scalp as pruritic, red macules, spreads to extremities
===[[Rash]]===
**W/in 24hr rash becomes vesicular (on erythematous base)
*Starts on trunk or scalp as pruritic, red macules, spreads to extremities
**Palms/soles spared
*Within 24hr rash becomes vesicular (on erythematous base)
**Lesions in various stages of development
**Often referred to as "dew drop on a rose petal" <ref name="Bode"/>
*Palms/soles spared
*Lesions in various stages of development
*The number of lesions can vary; usually 300 or less but can be more than 2,000 <ref name="Bode"/>
 
===Complications===
*Can include [[encephalitis]], [[otitis media]], [[pneumonia]], [[hepatitis]], [[strep]]/[[staph]] [[cellulitis|superinfection]] of ruptured vesicles
*Perinatal infection in neonates may develop serious illness


==Differential Diagnosis==
==Differential Diagnosis==
{{Peds Rash DDX}}
{{Peds Rash DDX}}
{{Bullous rashes DDX}}
{{VZV types}}


{{VZV types}}
==Evaluation==
*Typically made on clinical features


==Treatment==
==Management==
===Supportive Care===
===Supportive Care===
*Tylenol, antihistamine, oatmeal baths
*[[Tylenol]], [[antihistamine]], oatmeal baths
*Avoid aspirin in young children due to the risk of [[Reye syndrome]]
*Avoid aspirin in young children due to the risk of [[Reye syndrome]]


Line 33: Line 48:
*Patients receiving short, intermittent, or aerosolized courses of corticosteroids
*Patients receiving short, intermittent, or aerosolized courses of corticosteroids


Other cases to consider acyclovir
Other cases to consider [[acyclovir]]
*Also onsider in <ref>Drugs for non-HIV viral infections. Treat Guidel Med Lett. 2007; 5(59):59-70.</ref>:
*Also consider in <ref>Drugs for non-HIV viral infections. Treat Guidel Med Lett. 2007; 5(59):59-70.</ref>:
*Pregnancy<ref name="cdc">CDC Chicken pox acyclovir treatment [http://www.cdc.gov/chickenpox/hcp/persons-risk.html#acyclovir]</ref>
*Pregnancy<ref name="cdc">CDC Chicken pox acyclovir treatment [http://www.cdc.gov/chickenpox/hcp/persons-risk.html#acyclovir]</ref>
====Immunocompetent Adult====
====Immunocompetent Adult====
*Acyclovir 800mg PO q6hrs daily x 5 days OR
*[[Acyclovir]] 800mg PO q6hrs daily x 5 days '''OR'''
*Valacyclovir 1000mg PO q8hrs daily x 14 days OR
*[[Valacyclovir]] 1000mg PO q8hrs daily x 14 days '''OR'''
* Famiciclovir 500mg PO q8hrs x 14 days
*[[Famiciclovir]] 500mg PO q8hrs x 14 days
====Immunocompromised Adult====
====Immunocompromised Adult====
*Acyclovir 10mg/kg IV q8hrs x 7 days
*[[Acyclovir]] 10mg/kg IV q8hrs x 7 days
====At risk children <12yo child based on AAP criteria====
====At risk children <12yo child based on AAP criteria====
*Acyclovir 20mg/kg PO q6hrs daily x 5 days
*[[Acyclovir]] 20mg/kg PO q6hrs daily x 5 days
*Acyclovir 10mg/kg IV q8hrs daily x 7 days
*[[Acyclovir]] 10mg/kg IV q8hrs daily x 7 days
 
====VZIG====
*Initiate VZIG alongside acyclovir for inpatient treatment of child or adult
*For immunocompromised child with exposure, give as post-exposure prophylaxis if<ref>CDC. MMWR - updated recommendations for use of VariZIG - United States, 2013. July 19, 2013 / 62(28);574-576.</ref>:
**Within 10 days window of exposure
**VZIG given IM as 125 IU/10 kg of body weight
***Up to max of 625 IU
***Minimum dose 62.5 IU for patients weighing ≤ 2.0 kg
***Minimum dose 125 IU for weight 2.1 - 10.0 kg
*VZIG may prolong incubation period ≥1 week
**Must have patient closely follow up for signs and symptoms for 28 days after exposure
**If signs or symptoms of varicella occur, antiviral therapy must be started immediately
 
==Disposition==
*Most often discharge
*Secondary bacterial infection most common cause of hospitalization in kids
*Pneumonia most common cause of hospitalization in adults<ref>Reynolds MA, Watson BM, Plott-Adams KK, et al. Epidemiology of varicella hospitalizations in the United States, 1995-2005. J Infect Dis. 2008;197 Suppl 2:S120-S126. doi:10.1086/522146</ref>


==Complications==
==Vaccine==
*Can include encephalitis, otitis media, pneumonia, hepatitis, strep/staph superinfection of ruptured vesicles
*Introduced in 2006. Prior to introduction, incidence prior to adolescence approached 90% in US
*Perinatal infection in neonates may develop serious illness
*Vaccine is 85% effective against all disease, 90% effective against severe disease (greater than 1000 lesions)
*Typically given at age 5 in USA
*Post-exposure prophylaxis:
**Ideally given within 3-5 days of exposure in immunocompetent patients
**If immunocompromised patient is being given VZIG, varicella vaccine should be administered ≥5 months after VariZIG administration<ref>CDC. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2007;56(No. RR-4).</ref>


==See Also==
==See Also==
[[Pediatric Rashes]]
*[[Pediatric Rashes]]
*[[Varicella zoster virus]]


==Source==
==References==
<references/>
<references/>


[[Category:Derm]]
[[Category:Dermatology]]
[[Category:ID]]
[[Category:ID]]
[[Category:Peds]]
[[Category:Pediatrics]]

Latest revision as of 21:13, 12 July 2023

Background

  • Caused by varicella zoster virus causing varicella (chicken pox) and later zoster (Shingles)
  • Contagious until last lesion crusts over
    • Fluid from open vesicles contains live virus [1]
  • Incubation period is 10-21 days with symptoms starting around day 14 [1]

Herpes Virus Types

Clinical Features

Chickenpox rash on face.
Male with varicella rash: lesions in various stages of development
Classic blister during early stage of lesion development
  • Pruritic generalized vesicular exanthem with mild systemic manifestations
  • Usually affects children <10y

Rash

  • Starts on trunk or scalp as pruritic, red macules, spreads to extremities
  • Within 24hr rash becomes vesicular (on erythematous base)
    • Often referred to as "dew drop on a rose petal" [1]
  • Palms/soles spared
  • Lesions in various stages of development
  • The number of lesions can vary; usually 300 or less but can be more than 2,000 [1]

Complications

Differential Diagnosis

Pediatric Rash

Vesiculobullous rashes

Febrile

Afebrile

Varicella zoster virus

Evaluation

  • Typically made on clinical features

Management

Supportive Care

Antivirals

  • Routine use of antiretrovirals for uncomplicated cases in immunocompetent children is not recommended [2]
  • However, evidence shows decreased days of fever and number of lesions[3]

AAP recommends antiviral treatment (within 24hrs) for patients at risk of increased illness severity:

  • Any patient older than 12 years of age
  • Patients with chronic cutaneous or pulmonary disorders
  • Patients receiving long-term salicylate therapy
  • Patients receiving short, intermittent, or aerosolized courses of corticosteroids

Other cases to consider acyclovir

  • Also consider in [4]:
  • Pregnancy[5]

Immunocompetent Adult

Immunocompromised Adult

At risk children <12yo child based on AAP criteria

VZIG

  • Initiate VZIG alongside acyclovir for inpatient treatment of child or adult
  • For immunocompromised child with exposure, give as post-exposure prophylaxis if[6]:
    • Within 10 days window of exposure
    • VZIG given IM as 125 IU/10 kg of body weight
      • Up to max of 625 IU
      • Minimum dose 62.5 IU for patients weighing ≤ 2.0 kg
      • Minimum dose 125 IU for weight 2.1 - 10.0 kg
  • VZIG may prolong incubation period ≥1 week
    • Must have patient closely follow up for signs and symptoms for 28 days after exposure
    • If signs or symptoms of varicella occur, antiviral therapy must be started immediately

Disposition

  • Most often discharge
  • Secondary bacterial infection most common cause of hospitalization in kids
  • Pneumonia most common cause of hospitalization in adults[7]

Vaccine

  • Introduced in 2006. Prior to introduction, incidence prior to adolescence approached 90% in US
  • Vaccine is 85% effective against all disease, 90% effective against severe disease (greater than 1000 lesions)
  • Typically given at age 5 in USA
  • Post-exposure prophylaxis:
    • Ideally given within 3-5 days of exposure in immunocompetent patients
    • If immunocompromised patient is being given VZIG, varicella vaccine should be administered ≥5 months after VariZIG administration[8]

See Also

References

  1. 1.0 1.1 1.2 1.3 Sara Bode; Contagious Exanthematous Diseases. Quick References 2022; 10.1542/aap.ppcqr.396150
  2. Arvin AM: Antiviral therapy for varicella and herpes zoster. Semin Pediatr Infect Dis 2002; 13:12.
  3. Klassen TP, et al. Acyclovir for treating varicella in otherwise healthy children and adolescents. Cochrane Database Syst Rev. 2005; (4):CD002980.
  4. Drugs for non-HIV viral infections. Treat Guidel Med Lett. 2007; 5(59):59-70.
  5. CDC Chicken pox acyclovir treatment [1]
  6. CDC. MMWR - updated recommendations for use of VariZIG - United States, 2013. July 19, 2013 / 62(28);574-576.
  7. Reynolds MA, Watson BM, Plott-Adams KK, et al. Epidemiology of varicella hospitalizations in the United States, 1995-2005. J Infect Dis. 2008;197 Suppl 2:S120-S126. doi:10.1086/522146
  8. CDC. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2007;56(No. RR-4).